Rafferty Asset Management, LLC Revance Therapeutics, Inc. Transaction History

Rafferty Asset Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$4.65 - $9.31 $52,335 - $104,784	-11,255 Reduced 39.38%	17,325 $85,000
Q4 2023 Feb 13, 2024	BUY	$5.81 - $11.2 $46,997 - $90,596	8,089 Added 39.48%	28,580 $251,000
Q3 2023 Nov 13, 2023	BUY	$11.47 - $25.07 $131,652 - $287,753	11,478 Added 127.35%	20,491 $235,000
Q2 2023 Aug 11, 2023	BUY	$24.7 - $37.61 $48,510 - $73,866	1,964 Added 27.86%	9,013 $228,000
Q1 2023 May 11, 2023	SELL	$18.36 - $35.27 $101,549 - $195,078	-5,531 Reduced 43.97%	7,049 $227,000
Q4 2022 Feb 13, 2023	BUY	$18.32 - $30.66 $230,465 - $385,702	12,580 New	12,580 $232,000
Q2 2022 Aug 12, 2022	BUY	$11.52 - $20.4 $147,375 - $260,977	12,793 New	12,793 $177,000
Q1 2022 May 13, 2022	SELL	$12.36 - $20.31 $181,988 - $299,044	-14,724 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$12.46 - $27.87 $86,260 - $192,944	6,923 Added 88.75%	14,724 $240,000
Q3 2021 Nov 10, 2021	BUY	$25.78 - $33.21 $201,109 - $259,071	7,801 New	7,801 $217,000
Q1 2021 May 10, 2021	SELL	$24.03 - $29.97 $190,125 - $237,122	-7,912 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$23.41 - $28.34 $185,219 - $224,226	7,912 New	7,912 $224,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.